Rethinking Biotech’s Valley of Death as Federal Grants and Family Offices Step In

Summary

Early-stage biotechs are adapting financing strategies to leverage increased federal grant funding from the 2026 U.S. budget and capital from mission-driven family offices seeking nondilutive funding sources. This trend reflects industry efforts to navigate funding challenges through alternative capital sources beyond traditional venture funding.